The drugmaker has become a clear winner with its weight-loss drugs. Now, with a pill under development, the company should see earnings gains through the end of the decade.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...

Prices are falling for the popular obesity treatments Wegovy and Zepbound, but steady access to the drugs remains challenging ...

Pharmacy benefit manager CVS Caremark drops Zepbound coverage, estimating 10-15% savings while Eli Lilly offers self-pay ...

Doctors say the situation forces them to get creative in treating patients, but there’s hope that prices may fall more in the ...